Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion

TheFly reported connected January 13 that Leerink Partners lowered the terms people connected KURA to $20 from $25 and maintained an Outperform rating. This revision reflects updates to the exemplary incorporating preliminary Q4 fiscal results, which see Komzifti’s nett merchandise revenue, collaboration revenue, and 2026 guidance up of the company’s Q4 net report.

In addition, Kura Oncology, Inc. (NASDAQ:KURA) disclosed connected January 11 that KOMZIFTI (ziftomenib) generated $2.1 cardinal successful nett merchandise income during the archetypal 5 weeks of commercialized availability, which ended connected December 31, 2025. The archetypal oral menin inhibitor approved for usage erstwhile regular successful patients with refractory oregon relapsed NPM1-mutated acute myeloid leukemia (AML) is called KOMZIFTI.

The concern recognized advancements in all of its TSHA-102 improvement programs and outlined anticipated 2026 milestones. These accomplishments included expanding ziftomenib into operation regimens and non-AML indications, expanding the commercialized usage of KOMZIFTI, and progressing existent AML objective investigations.

Kura Oncology, Inc. (NASDAQ:KURA) is simply a clinical‑stage biopharmaceutical institution discovering and processing targeted therapies for crab and hematologic malignancies. Its pipeline includes precision small‑molecule inhibitors aimed astatine cardinal oncogenic drivers, to present effective, well‑tolerated treatments that amended diligent outcomes successful genetically defined crab populations.

While we admit the imaginable of KURA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.